Bioscience

Biozona Weekly: PCH undertakes whole genome sequencing; Integrative medicine becoming more popular; Six companies awarded Innovation Challenge grants

January 11, 2013

By Flinn Foundation

Tucson Tech: NuvOx drug that aids radiation treatments set for clinical trials
1/8/2013 | Arizona Daily Star | David Wichner

A four-year-old Tucson company, NuvOx Pharma, is planning clinical trials of an injectable drug that can infuse tumors with oxygen to make them more susceptible to radiation treatment.

PCH undertakes whole-genome sequencing for cancer treatment

1/4/2013 | Phoenix Business Journal | Christopher Leone

The technological advancements in whole genome sequencing are making it possible for geneticists, oncologists and pathologists to start applying whole genome sequencing, or WGS, on a patient-by-patient basis. Phoenix Children’s Hospital will be one of the first to do that.

Integrative medicine is growing in popularity
1/3/2013 | Arizona Republic | Ken Alltucker

Doctors are paving the way for integrative medicine, a term coined and popularized by the University of Arizona’s Dr. Andrew Weil. Although definitions of the emerging health field vary, it generally describes the practice of combining conventional medicine with complementary and alternative medical techniques that are supported by medical literature or evidence.

Science grant will boost STEM genomic project
12/23/2012 | Daily Sun | Staff report

Science Foundation Arizona has awarded a $25,000 grant to Flagstaff STEM Connections for a pilot program focused on teaming up 15 Flagstaff Unified School District teachers with 15 faculty members from the NAU Center for Science Teaching and Learning.

Arizona Commerce Authority tabs 6 companies for Innovation Challenge awards
12/21/2012 | Phoenix Business Journal | Patrick O’Grady

The Arizona Commerce Authority has named six companies to receive Innovation Challenge grants as part of its semi-annual contest which aims to provide up to $250,000 in seed funding to startups to help them progress to commercialization of their products.